<DOC>
	<DOCNO>NCT01588184</DOCNO>
	<brief_summary>This single-arm , open-label , multicentre extension study provide continue Avastin [ bevacizumab ] therapy patient solid tumour previously enrol Roche/Genentech sponsor study derive benefit Avastin therapy . Patients receive dose regimen use previous parent trial continue treatment disease progression unacceptable toxicity .</brief_summary>
	<brief_title>An Extension Study Provide Continued Avastin Therapy Patients With Solid Tumours Who Were Previously Enrolled Roche/Genentech Sponsored Study</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Patients solid tumour Patient treat Avastin end Roche/Genentech sponsor parent trial continue benefit Avastin treatment Eligible continuation Avastin treatment end parent trial Able comply extension study protocol ( MO25757 ) Evidence disease progression Evidence adverse event potentially attributable Avastin , permanent treatment discontinuation recommend A treatment interruption Avastin 42 day since last administration Avastin parent trial Any disease would put patient high risk treatmentrelated complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>